Wallenberg's Syndrome |
|
|
Clinical Trial: The effect of androgen and growth hormone on height and learning in girls with Turner syndrome
This study is no longer recruiting patients.
|
Purpose
The purposes of this study are to learn whether treatment with an androgen type hormone will improve the visual-spatial problems associated with Turner syndrome, and to evaluate the effect growth hormone, with and without androgen, has on growth.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Turner Syndrome | Drug: estrogen Drug: androgen | Phase III |
MedlinePlus related topics: Turner's Syndrome
Genetics Home Reference related topics: Turner syndrome
Study Type: Interventional
Study Design: Treatment, Randomized
Official Title: The effects of androgen, estrogen, and the combination of androgen and estrogen on growth rate and cognitive function of growth hormone-treated girls with Turner syndrome
Expected Total Enrollment: 200
Study start: November 1992
Turner syndrome is associated with short stature, multiple physical stigmata, absent pubertal development, and increased learning problems. This study is designed to (1) examine the effects of sex steroids (androgen and estrogen) on multiple variables including growth rate, GH binding protein, IGF-I, IGFBP3, and cognitive function in the setting of supplemental growth hormone administration and (2) to investigate any synergistic or additive effects of the androgen and estrogen combination versus each alone, on the above variables.
Eligibility
Ages Eligible for Study: 10 Years - 14 Years, Genders Eligible for Study: Female
Criteria
- Karyotype diagnosis compatible with Turner syndrome, but no presence of any Y material in the peripheral karyotype unless a gonadectomy has been performed;
- Chronological age between 10.0 and 14.9 years;
- Bone age less than or equal to 12 years; and
- No treatment with estrogen, androgen, growth hormone, or any other growth-promoting agents exceeding 12 months, and no treatment with any of these agents in the previous 3 months.
Location Information
Maryland
National Institutes of Health, Bethesda, Maryland, 20892, United States
Pennsylvania
Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 726, Philadelphia, Pennsylvania, 19102, United States
Judith L. Ross, M.D., Principal Investigator, Thomas Jefferson University Hospital
More Information
Record last reviewed: July 2004
Last Updated: October 13, 2004
Record first received: January 8, 2002
ClinicalTrials.gov Identifier: NCT00029159
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


